DME is different to other retinal vascular diseases and requires individualised treatment approaches1-4
DME is characterised by inflammation, angiogenesis, blood vessel damage and edema.5-7 DME differs from age-related macular degeneration (AMD) which is associated with abnormal blood vessel growth.1
Patients with DME may also suffer from other diabetes-related comorbidities. This can mean they may be burdened with a high number of hospital appointments – usually having to attend more appointments than AMD patients. This treatment burden can be hard for DME patients with active work and family lives.2,3
Efficacy, safety and treatment injection frequency are all factors that should be considered when treating DME.4,8
OZURDEX® is a dexamethasone intravitreal implant, with clinical and real world data in DME9,10
OZURDEX® mechanism of action
• OZURDEX® targets inflammation significant to the pathogenesis of DME9,12-14
• OZURDEX® has been shown to reduce DME through anti-inflammatory effects, vascular effects and by activating draining mechanisms*9,12-16
*Supporting evidence includes data from animal models
Real world data and durability with OZURDEX®
• Visual acuity data in suitable naïve and refractory eyes10,17
• Sustained release of dexamethasone with retreatment after approximately 6 months9
Abbreviations and references
DME, diabetic macular edema; AMD, age-related macular degeneration.
1. Bhutto I and Lutty G. Mol Aspects Med 2012; 33(4): 295-317.
2. Sivaprasad S and Oyetunde S. Clin Ophthalmol 2016; 24(10): 939-46.
3. Rose MA et al. Clin Exp Ophth 2020. https://doi.org/10.1111/ceo.13845.
4. Kodjikian L et al. Eur J Ophthalmol 2019; 29(6): 573-84.
5. Urias EA et al. Vision Res 2017; 139: 221-7.
6. Bahrami B et al. Diabetologia 2016; 59: 1594-608.
7. Munk MR et al. Int J Mol Sci 2022; 23: 7585. https://doi.org/10.3390/ijms23147585.
8. Schmidt-Erfurth et al. Ophthalmologica 2017; 237: 185-222.
9. OZURDEX® SPC.
10. Kodjikian L et al. BioMed Research International 2018. https://doi.org10.1155/2018/8289253.
11. Noma H et al. Int J Mol Sci 2021; 22: 3427. https://doi.org/10.3390/ijms22073427.
12. Nehme A and Edelman J. Invest Ophthalmol Vis Sci 2008; 49(5): 203-8.
13. Wang K et al. Biol Pharm Bull 2008; 31(8): 1541-6.
14. Siqueiros-Marquez L et al. Invest Ophthalmol Vis Sci 2017; 58(2): 876-86.
15. Zhao M et al. Invest Ophthalmol Vis Sci 2011; 52(9): 6340-7.
16. Garcia-Layana A et al. Ophthalmologica 2018; 240(2): 61-72.
17. Hernández Martínez A et al. Eur J Ophthalmol 2020; 30(5): 1091-8.
Job Number ALL-OZU-220048. Date of Preparation March 2023
OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:
- Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently
responsive to, or unsuitable for non-corticosteroid therapy - Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis
Adverse events should be reported. Reporting forms and information can be found at XXXX
Adverse events should also be reported to AbbVie on GVPV@abbvie.com
Our therapy areas
Additional info
Report Adverse Event (AE reporting requirements to be localized)
This website is for Healthcare Professionals only
Job Number ALL-OZU-220048. Date of Preparation March 2023. This website has been developed and funded by AbbVie Ltd.
© 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.